BD Issues Nationwide Recall for Specific Lots of BD® Intraosseous Vascular Access System Needle Sets Due to Reports of Difficulty Removing the Obturator
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dental sedation and oral surgery practices that rely on intraosseous anesthesia or emergency vascular access must immediately quarantine affected BD needle-set lots; difficulty removing the obturator could delay treatment or cause device failure mid-procedure.
Key points
- Recall covers specific lots of BD® Intraosseous Vascular Access System Needle Sets announced 31 Jul 2026; FDA Class I-level action.
- Risk: obturator may stick, prolonging procedure time or forcing an unplanned switch to alternative vascular access in medically compromised dental patients.
- Action required: check lot numbers against the recall list, remove affected stock, and contact BD for replacement before next sedation or surgical case.
- Primarily impacts oral & maxillofacial surgeons, periodontists placing implants under sedation, and any practice maintaining medical-emergency kits with IO capability.
Who should care
Read the original on FDA Recalls
Full reporting and any paywall content live on fda.gov. We summarize and score; we do not republish.
Related
- ·Business
‘Surviving your own balance sheet’: The operational challenges weighing DSOs down
- ·Regulatory
ADHA opposes Nevada bill allowing hygienists to skip accredited training
- ·Business
23% of dentists have dropped insurers so far in 2026
- ·Business
Dental reimbursement rates not keeping pace with inflation: ADA